JFS Wealth Advisors LLC lifted its position in shares of GSK plc (NYSE:GSK - Free Report) by 1,429.4% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,426 shares of the pharmaceutical company's stock after buying an additional 27,502 shares during the quarter. JFS Wealth Advisors LLC's holdings in GSK were worth $1,203,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of GSK. Cohen Investment Advisors LLC purchased a new stake in GSK in the 2nd quarter worth $349,000. Blair William & Co. IL lifted its stake in GSK by 14.9% in the 1st quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company's stock worth $1,007,000 after purchasing an additional 3,044 shares in the last quarter. SG Americas Securities LLC lifted its stake in GSK by 448.7% in the 1st quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company's stock worth $758,000 after purchasing an additional 14,466 shares in the last quarter. Royal Fund Management LLC lifted its stake in GSK by 87.0% in the 3rd quarter. Royal Fund Management LLC now owns 42,456 shares of the pharmaceutical company's stock worth $1,737,000 after purchasing an additional 19,758 shares in the last quarter. Finally, CreativeOne Wealth LLC purchased a new stake in shares of GSK during the 1st quarter valued at about $235,000. Hedge funds and other institutional investors own 15.74% of the company's stock.
GSK Trading Up 0.3 %
NYSE:GSK traded up $0.11 during mid-day trading on Friday, hitting $36.87. 6,876,973 shares of the stock traded hands, compared to its average volume of 3,858,042. The stock has a market capitalization of $76.41 billion, a price-to-earnings ratio of 24.10, a PEG ratio of 1.23 and a beta of 0.65. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The firm's 50 day moving average is $40.78 and its two-hundred day moving average is $41.05. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99.
GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. The company had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a net margin of 7.97% and a return on equity of 51.23%. On average, equities research analysts predict that GSK plc will post 4.08 earnings per share for the current year.
GSK Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a $0.3928 dividend. This is an increase from GSK's previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.26%. The ex-dividend date of this dividend is Friday, November 15th. GSK's dividend payout ratio is currently 98.70%.
Insiders Place Their Bets
In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company's stock in a transaction on Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.00% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. UBS Group cut shares of GSK from a "buy" rating to a "neutral" rating in a research report on Monday, July 8th. Guggenheim cut shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday. Argus upgraded shares of GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Finally, Barclays upgraded shares of GSK to a "hold" rating in a research report on Tuesday, August 27th. Five research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $50.00.
Check Out Our Latest Stock Analysis on GSK
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
